Drug Trial Radar · NCT07509242
Comparative Efficacy of hUCMSC-Secretome Delivered Via Microneedling and Intradermal Microinjection as Adjuvant Therapy to NB-UVB in Nonsegmental Vitiligo: A Quasi-Experimental Study
Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Mar 18, 2026
Primary completion
Jan 18, 2027
Study completion Jan 18, 2028
Sponsor
- Lead sponsor
- Yohanes Firmansyah, dr, MH, MMAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to analyze the effectiveness of SM-hUCMSC secretome administered via microneedling and intradermal microinjection as adjuvant therapy to NB-UVB, compared with NB-UVB alone, in terms of repigmentation, onset of improvement, safety, patient satisfaction, and vitiligo recurrence. The main questions it aims to answer are: * Are there differences in the level of vitiligo lesion repigmentation among the secretome therapy via microneedling, intradermal microinjection, and NB-UVB phototherapy groups? * Are there differences in the time to onset of repigmentation among the treatment groups? What are the safety profiles and adverse events associated with each treatment modality? * Are there differences in patient satisfaction and quality of life after undergoing each therapy? * Are there differences in vitiligo recurrence rates during the follow-up period among the treatment groups? Participants will be allocated into three groups as follows: * Group A receives NB-UVB combined with microneedling and topical 10% secretome. * Group B receives NB-UVB combined with intradermal secretome injection. * Group C receives NB-UVB alone. The intervention period lasts 12 weeks, with follow-up until week 24.
Conditions
- Vitiligo
Interventions
NB-UVB combined with microneedling and topical 10% secretomeOther
Group A receives NB-UVB combined with microneedling and topical 10% secretome.
receives NB-UVB combined with intradermal secretome injectionOther
Group B receives NB-UVB combined with intradermal secretome injection
NB-UVB aloneDrug
Group C receives NB-UVB alone
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients Achieving ≥50% Repigmentation Assessed by Vitiligo Area Scoring Index (VASI)Time frame: Baseline, Week 4, Week 8, Week 12 (primary endpoint), and Week 24 (follow-up)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Klinik Precious Me
Tangerang, Banten, Indonesia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.